ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...-non-small-cell-lung-cancer-R-NSCLC-LACE-Bio

AimThe precise selection of patients for ACT is critical but there remain no validated molecular tools which are prognostic for relapse or predictive of benefit from ACT.

Date: 27 Sep 2014
Presenter: Lesley Seymour
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Early Stage, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...-role-and-disease-free-survival-DFS-by-stage

AimIn patients (pts) with advanced NSCLC (stage IIIB/IV), EGFR M+ is predictive of response to EGFR-TKI; data on its prognostic role are mixed. RADIANT, a randomized (2:1) phase 3 trial of erlotinib ...

Date: 27 Sep 2014
Presenter: Nasser Altorki
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...re-EGFR-mutations-EGFRm-in-the-RADIANT-trial

AimData on EGFRm in early stage NSCLC are limited. RADIANT was a large prospectively randomized Ph3 trial of adjuvant erlotinib (E) v placebo (P) in patients (pts) with completely resected Stage IB to...

Date: 27 Sep 2014
Presenter: Wilfried Eberhardt
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...vited-discussant-abstracts-1177PD-and-1178PD

Date: 27 Sep 2014
Presenter: Tetsuya Mitsudomi
Resources: Presentation, Webcast
Topic: Non-Small-Cell Lung Cancer, Early Stage

http://oncologypro.esmo.org/Meeting-Resourc...-cancer-patients-with-multiple-lung-relapses

AimPatients with early stage non-small cell lung cancer (NSCLC) undergo surgical removal of their tumors. However, in some individuals tumors can recur and are re-removed multiple times.

Date: 27 Sep 2014
Presenter: Antonio Calles
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Pathology/Molecular Biology, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...cording-to-clinical-and-pathological-factors

AimThe aim of this preliminary analysis (AIRC-MFAG project 14282) was to define a risk classification for R-SQLC on the basis of the combination of clinical and pathological predictors, to provide a...

Date: 27 Sep 2014
Presenter: Emilio Bria
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...er.-A-competing-risk-and-multistate-approach

AimDuring the last decade, adjuvant cisplatin-based chemotherapy has become the standard therapy against resected non-small cell lung cancer (NSCLC) following two meta-analyses of randomised trials...

Date: 27 Sep 2014
Presenter: Federico Rotolo
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Early Stage

http://oncologypro.esmo.org/Meeting-Resourc...kers-in-tumor-and-stroma-in-resectable-NSCLC

AimTumor-infiltrating immune cells have been proved to play an important role in tumor progression. In this study we have analyzed the expression of 11 immune related genes in both tumor and stroma samples of resectable NSCLC patients.

Date: 27 Sep 2014
Presenter: Marta Usó
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...sis-of-clinical-stage-IA-lung-adenocarcinoma

AimHigh maximum standardized uptake values (SUVmax) on [18F]-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) have been demonstrated to be associated with inferior survival in lung adenocarcinoma.

Date: 27 Sep 2014
Presenter: Yoshihiro Miyata
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Imaging, Diagnosis and Staging, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...-and-lepidic-predominant-lung-adenocarcinoma

AimThe new International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society (IASLC/ATS/ERS) lung adenocarcinoma classification has been proposed in 2011.

Date: 27 Sep 2014
Presenter: Jung-Jyh Hung
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Pathology/Molecular Biology